Fennec Pharmaceuticals Inc.
FENC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001211583
In the last 90 days, Fennec Pharmaceuticals Inc. insiders filed 0 open-market purchases and 5 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $175.1M in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Fennec Pharmaceuticals Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 56 | 55 | −1 |
| Shares | 14.1M | 14.3M | +225.1K (+1.6%) |
| Value | $124.5M | $107.6M | −$16.9M (−13.6%) |
New holders (3)
Institutions that held Fennec Pharmaceuticals Inc. at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Allspring Global Investments Holdings, LLC | 6,705 | $50.4K | 0.00% |
| Ronald Blue Trust, Inc. | 2,367 | $21.0K | 0.00% |
| Russell Investments Group, Ltd. | 321 | $2.41K | 0.00% |
Sold out (4)
Institutions that held Fennec Pharmaceuticals Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Millennium Management LLC | 86,794 | $766.4K |
| Two Sigma Investments, LP | 13,561 | $119.7K |
| Susquehanna International Group, LLP | 11,429 | $100.9K |
| Trellus Management Company, LLC | 10,561 | $93.3K |